Prime Highlights
- The EU Council has backed updated rules introducing a faster regulatory pathway for certain genetically modified micro-organisms meeting set safety standards.
- Surgeons performing emergency autologous organ transplants will face fewer regulatory restrictions under the newly clarified provisions.
Key Facts
- The European Biotech Act I directive amends existing EU legislation on GMMs and organ processing to reflect scientific advances and reduce regulatory bottlenecks.
- GMM market consent will initially be valid for up to ten years, with the option for indefinite renewal upon reassessment.
Background
The European Union Council has agreed on its position regarding targeted changes to health legislation aimed at strengthening the bloc’s biotechnology sector and modernising organ transplant rules.
The draft European Biotech Act I directive proposes amendments to two existing laws, one governing genetically modified micro-organisms (GMMs) and another covering organ processing. Such changes aim to streamline the process of bringing innovative products from the laboratory stage to the market.
Within the context of the new GMM regulation framework, there is going to be a more streamlined approval process for some GMMs that will be shown to comply with certain predetermined safety standards. In place of the previous notion of low-risk GMMs, the Council decided to use “GMMs for which an expedited procedure applies” in order not to suggest that the other GMMs were high-risk. Approval for the GMMs would have an initial period of ten years, after which renewal could be extended indefinitely with certain exceptions.
Regarding organ transplantation, the proposed changes take into consideration the scientific advancements that now permit longer periods between removal and transplantation. The Council managed to distinguish two types of transplantation procedures: autologous transplantation (transplantation of organs from the same individual), which is usually done under emergency conditions, and transplantation between two individuals.
Another provision of the stance taken by the council includes the processing of personal information where it pertains to organ transplants, under the pretence of public interest. The intention behind this provision is to maintain patient safety and allow the exchange of data between countries to aid transplant analysis.
The directive’s language is clarified under the mandate of the Council.
